GlassScriptPhysician profile
William Bernard Hebda
NPI 1417051681
$3,456.70
in general payments reported to CMS, 2019-2025
42 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $118 · 2021: $550 · 2022: $575 · 2023: $315 · 2024: $836 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $676.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $522.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $300.38 | 2021-2025 | |
| Pfizer INC. | $269.91 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.84 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $147.64 | 2019-2025 | Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $136.87 | 2019-2022 | |
| Amgen INC. | $126.22 | 2019-2025 | Repatha, Otezla, Otezla |
| Otsuka America Pharmaceutical, INC. | $116.48 | 2021-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $96.51 | 2021-2022 | |
| Glaxosmithkline, LLC. | $96.31 | 2019-2023 | Shingrix, Arexvy |
| Eisai INC. | $60.22 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $55.04 | 2019-2025 | Capvaxive, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $51.32 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $44.59 | 2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hebda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.